Novavax Inc (NVAX)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$7.20
Buy
$7.25
$-0.04 (-0.55%)
Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
Prices updated at 24 May 2025, 00:59 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
| Year | Gross margin (%) | Operating margin (%) | Net margin (%) | EBITDA margin (%) | EBITDA |
|---|---|---|---|---|---|
| 2024 | 70.28 | -36.49 | -27.49 | -15.84 | -108m |
| 2023 | 38.21 | -101.82 | -97.97 | -87.60 | -487m |
| 2022 | 43.55 | -40.32 | -41.15 | -37.82 | -605m |
| 2021 | 100.00 | -853.61 | -882.55 | -850.66 | -1,681m |
| 2020 | 100.00 | -1,861.35 | -1,868.23 | -1,778.76 | -398m |
| 2019 | - | -694.44 | -711.04 | -615.31 | -115m |
| 2018 | - | -507.23 | -538.81 | -479.47 | -164m |
| 2017 | - | -550.78 | -589.46 | -512.83 | -160m |
| 2016 | - | -1,752.84 | -1,823.53 | -1,683.68 | -258m |
Valuation data table
| Year | Price / Sales | Price earnings | Price / Cash flow |
|---|---|---|---|
| 2025 | 0.96 | 2.64 | - |
| 2024 | 1.36 | - | - |
| 2023 | 0.73 | - | - |
| 2022 | 0.43 | - | - |
| 2021 | 8.55 | - | 19.17 |
| 2020 | 26.22 | - | 86.18 |
| 2019 | 5.45 | - | - |
| 2018 | 16.84 | - | - |
| 2017 | 13.34 | - | - |
| 2016 | 21.56 | - | - |
| 2015 | 57.51 | - | - |
Price/Forward earnings (YTD)
-6.78
Returns
Debt profile
Returns data table
| Year | Return on assets (%) | Return on equity (%) | Return on invested capital (%) |
|---|---|---|---|
| 2024 | -11.17 | - | - |
| 2023 | -26.88 | - | - |
| 2022 | -27.21 | - | - |
| 2021 | -83.85 | -1,265.72 | -288.65 |
| 2020 | -47.65 | -189.60 | -65.49 |
| 2019 | -69.67 | - | - |
| 2018 | -72.38 | - | - |
| 2017 | -52.75 | - | - |
| 2016 | -71.75 | -195.01 | -58.06 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2024 | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | 2.52 |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
